These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 9661080

  • 1. Treatment with the oral growth hormone secretagogue MK-677 increases markers of bone formation and bone resorption in obese young males.
    Svensson J, Ohlsson C, Jansson JO, Murphy G, Wyss D, Krupa D, Cerchio K, Polvino W, Gertz B, Baylink D, Mohan S, Bengtsson BA.
    J Bone Miner Res; 1998 Jul; 13(7):1158-66. PubMed ID: 9661080
    [Abstract] [Full Text] [Related]

  • 2. Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group.
    Murphy MG, Bach MA, Plotkin D, Bolognese J, Ng J, Krupa D, Cerchio K, Gertz BJ.
    J Bone Miner Res; 1999 Jul; 14(7):1182-8. PubMed ID: 10404019
    [Abstract] [Full Text] [Related]

  • 3. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
    Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, Gertz BJ, MK-677/Alendronate Study Group.
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
    [Abstract] [Full Text] [Related]

  • 4. High serum IGFBP-2 is predictive of increased bone turnover in aging men and women.
    Amin S, Riggs BL, Melton LJ, Achenbach SJ, Atkinson EJ, Khosla S.
    J Bone Miner Res; 2007 Jun; 22(6):799-807. PubMed ID: 17352648
    [Abstract] [Full Text] [Related]

  • 5. Serum levels of insulin-like growth factor binding proteins (IGFBP)-4 and -5 correlate with bone mineral density in growth hormone (GH)-deficient adults and increase with GH replacement therapy.
    Thorén M, Hilding A, Brismar T, Magnusson P, Degerblad M, Larsson L, Sääf M, Baylink DJ, Mohan S.
    J Bone Miner Res; 1998 May; 13(5):891-9. PubMed ID: 9610754
    [Abstract] [Full Text] [Related]

  • 6. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure.
    Svensson J, Lönn L, Jansson JO, Murphy G, Wyss D, Krupa D, Cerchio K, Polvino W, Gertz B, Boseaus I, Sjöström L, Bengtsson BA.
    J Clin Endocrinol Metab; 1998 Feb; 83(2):362-9. PubMed ID: 9467542
    [Abstract] [Full Text] [Related]

  • 7. Short-term treatment with growth hormone stimulates osteoblastic and osteoclastic activity in osteopenic postmenopausal women: a dose response study.
    Brixen K, Kassem M, Nielsen HK, Loft AG, Flyvbjerg A, Mosekilde L.
    J Bone Miner Res; 1995 Dec; 10(12):1865-74. PubMed ID: 8619366
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Treatment of obese subjects with the oral growth hormone secretagogue MK-677 affects serum concentrations of several lipoproteins, but not lipoprotein(a).
    Svensson J, Jansson JO, Ottosson M, Johannsson G, Taskinen MR, Wiklund O, Bengtsson BA.
    J Clin Endocrinol Metab; 1999 Jun; 84(6):2028-33. PubMed ID: 10372705
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Growth hormone (GH) effects on bone and collagen turnover in healthy adults and its potential as a marker of GH abuse in sports: a double blind, placebo-controlled study. The GH-2000 Study Group.
    Longobardi S, Keay N, Ehrnborg C, Cittadini A, Rosén T, Dall R, Boroujerdi MA, Bassett EE, Healy ML, Pentecost C, Wallace JD, Powrie J, Jørgensen JO, Saccà L.
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1505-12. PubMed ID: 10770189
    [Abstract] [Full Text] [Related]

  • 13. Changes of bone markers during long-term intravenous calcitriol therapy in maintenance dialysis patients.
    Lee SH, Huang TS, Hsieh SJ.
    Miner Electrolyte Metab; 1996 Apr; 22(4):219-23. PubMed ID: 8807625
    [Abstract] [Full Text] [Related]

  • 14. Normal osteoclastic and osteoblastic responses to exogenous growth hormone in patients with postmenopausal spinal osteoporosis.
    Kassem M, Brixen K, Blum WF, Mosekilde L, Eriksen EF.
    J Bone Miner Res; 1994 Sep; 9(9):1365-70. PubMed ID: 7817819
    [Abstract] [Full Text] [Related]

  • 15. Intestinal calcium absorption and bone metabolism in young adult men with childhood-onset growth hormone deficiency.
    de Boer H, Blok GJ, Popp-Snijders C, Sips A, Lips P, van der Veen E.
    J Bone Miner Res; 1998 Feb; 13(2):245-52. PubMed ID: 9495517
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effect of calcium fortified milk supplementation with or without vitamin K on biochemical markers of bone turnover in premenopausal women.
    Kruger MC, Booth CL, Coad J, Schollum LM, Kuhn-Sherlock B, Shearer MJ.
    Nutrition; 2006 Feb; 22(11-12):1120-8. PubMed ID: 17030114
    [Abstract] [Full Text] [Related]

  • 19. Body mass index (BMI) and parameters of bone formation and resorption in postmenopausal women.
    Papakitsou EF, Margioris AN, Dretakis KE, Trovas G, Zoras U, Lyritis G, Dretakis EK, Stergiopoulos K.
    Maturitas; 2004 Mar 15; 47(3):185-93. PubMed ID: 15036488
    [Abstract] [Full Text] [Related]

  • 20. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
    Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, Glass EV, Myers SL, Krege JH.
    J Bone Miner Res; 2005 Nov 15; 20(11):1905-11. PubMed ID: 16234962
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.